228 related articles for article (PubMed ID: 23002203)
21. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
Gumireddy K; Baker SJ; Cosenza SC; John P; Kang AD; Robell KA; Reddy MV; Reddy EP
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):1992-7. PubMed ID: 15677719
[TBL] [Abstract][Full Text] [Related]
22. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
[TBL] [Abstract][Full Text] [Related]
23. Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.
Khateb M; Ruimi N; Khamisie H; Najajreh Y; Mian A; Metodieva A; Ruthardt M; Mahajna J
BMC Cancer; 2012 Nov; 12():563. PubMed ID: 23186157
[TBL] [Abstract][Full Text] [Related]
24. Allosteric inhibitors of Bcr-Abl: towards novel myristate-pocket binders.
Radi M; Schenone S; Botta M
Curr Pharm Biotechnol; 2013; 14(5):477-87. PubMed ID: 22429131
[TBL] [Abstract][Full Text] [Related]
25. Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
Grebien F; Hantschel O; Wojcik J; Kaupe I; Kovacic B; Wyrzucki AM; Gish GD; Cerny-Reiterer S; Koide A; Beug H; Pawson T; Valent P; Koide S; Superti-Furga G
Cell; 2011 Oct; 147(2):306-19. PubMed ID: 22000011
[TBL] [Abstract][Full Text] [Related]
26. Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.
El Rashedy AA; Olotu FA; Soliman MES
Chem Biodivers; 2018 Mar; 15(3):e1700533. PubMed ID: 29325229
[TBL] [Abstract][Full Text] [Related]
27. Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.
Carofiglio F; Trisciuzzi D; Gambacorta N; Leonetti F; Stefanachi A; Nicolotti O
Molecules; 2020 Sep; 25(18):. PubMed ID: 32937901
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
[TBL] [Abstract][Full Text] [Related]
29. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
30. Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL.
Zhan JY; Ma J; Zheng QC
J Mol Graph Model; 2019 Jun; 89():242-249. PubMed ID: 30927708
[TBL] [Abstract][Full Text] [Related]
31. Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.
Vrontaki E; Melagraki G; Voskou S; Phylactides MS; Mavromoustakos T; Kleanthous M; Afantitis A
Mini Rev Med Chem; 2017; 17(3):188-204. PubMed ID: 28143387
[TBL] [Abstract][Full Text] [Related]
32. How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study.
Zhang H; He X; Ni D; Mou L; Chen X; Lu S
J Biomol Struct Dyn; 2020 Jan; 38(1):89-100. PubMed ID: 30661457
[TBL] [Abstract][Full Text] [Related]
33. CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.
Gu Y; Chen T; Meng Z; Gan Y; Xu X; Lou G; Li H; Gan X; Zhou H; Tang J; Xu G; Huang L; Zhang X; Fang Y; Wang K; Zheng S; Huang W; Xu R
Blood; 2012 Dec; 120(24):4829-39. PubMed ID: 23074277
[TBL] [Abstract][Full Text] [Related]
34. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
Million RP; Van Etten RA
Blood; 2000 Jul; 96(2):664-70. PubMed ID: 10887132
[TBL] [Abstract][Full Text] [Related]
35. Structure of the Bcr-Abl oncoprotein oligomerization domain.
Zhao X; Ghaffari S; Lodish H; Malashkevich VN; Kim PS
Nat Struct Biol; 2002 Feb; 9(2):117-20. PubMed ID: 11780146
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of thiadiazoles and thiazoles targeting the Bcr-Abl T315I mutant: from docking false positives to ATP-noncompetitive inhibitors.
Radi M; Crespan E; Falchi F; Bernardo V; Zanoli S; Manetti F; Schenone S; Maga G; Botta M
ChemMedChem; 2010 Aug; 5(8):1226-31. PubMed ID: 20509136
[No Abstract] [Full Text] [Related]
37. Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
Lamontanara AJ; Gencer EB; Kuzyk O; Hantschel O
Biochim Biophys Acta; 2013 Jul; 1834(7):1449-59. PubMed ID: 23277196
[TBL] [Abstract][Full Text] [Related]
38. Ensemble-based virtual screening: identification of a potential allosteric inhibitor of Bcr-Abl.
Singh VK; Coumar MS
J Mol Model; 2017 Jul; 23(7):218. PubMed ID: 28669127
[TBL] [Abstract][Full Text] [Related]
39. Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL.
Mian AA; Oancea C; Zhao Z; Ottmann OG; Ruthardt M
Leukemia; 2009 Dec; 23(12):2242-7. PubMed ID: 19798092
[TBL] [Abstract][Full Text] [Related]
40. Expanding the diversity of allosteric bcr-abl inhibitors.
Deng X; Okram B; Ding Q; Zhang J; Choi Y; Adrián FJ; Wojciechowski A; Zhang G; Che J; Bursulaya B; Cowan-Jacob SW; Rummel G; Sim T; Gray NS
J Med Chem; 2010 Oct; 53(19):6934-46. PubMed ID: 20828158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
